Tim Chiang
Stock Analyst at Capital One
(1.11)
# 3,497
Out of 4,784 analysts
21
Total ratings
31.25%
Success rate
-5.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $2.26 | +165.49% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $48.88 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $4.46 | +1,469.51% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $28.43 | +54.77% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $6.05 | +3,205.79% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $24.91 | +164.95% | 3 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $1.05 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $21 | $0.43 | +4,749.88% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $15.08 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $20.32 | +62.40% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $2.26
Upside: +165.49%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $48.88
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $4.46
Upside: +1,469.51%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $28.43
Upside: +54.77%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $6.05
Upside: +3,205.79%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $24.91
Upside: +164.95%
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $21
Current: $0.43
Upside: +4,749.88%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $15.08
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $20.32
Upside: +62.40%